CytoSorb血液灌流显著降低人体内全身炎症时的循环细胞因子浓度
该研究采用重复人体实验性内毒素血症模型,24名健康男性志愿者在第0天和第7天接受LPS静脉攻击(1 ng/kg推注后0.5 ng/kg/hr持续输注3小时),首次攻击时随机接受CytoSorb血液灌流或无干预。结果显示,与对照组相比,CytoSorb组首次LPS攻击期间血浆TNF降低58%(p<0.0001)、IL-6降低71%(p=0.003)、IL-8降低48%(p=0.02)、IL-10降低26%(p=0.03),而第二次攻击时两组细胞因子反应无差异。作者认为CytoSorb血液灌流可有效降低人体全身炎症时的循环细胞因子浓度,但不影响长期免疫功能,可能对细胞因子过度释放的疾病状态有益。
要点
- 在健康男性志愿者中,首次LPS攻击时CytoSorb组较对照组血浆TNF降低58%(p<0.0001)、IL-6降低71%(p=0.003)。
- 同一模型中,CytoSorb组IL-8降低48%(p=0.02)、IL-10降低26%(p=0.03),均具统计学显著性。
- 第二次LPS攻击时两组细胞因子反应无差异,提示CytoSorb不影响长期免疫功能。
- 作者认为CytoSorb疗法可能对以细胞因子过度释放为特征的疾病状态有益。
适用人群与场景
- 健康男性志愿者,年龄18-35岁,共24人,接受静脉LPS攻击以建立全身炎症与免疫耐受模型。
处置流程与药物剂量
- LPS攻击方案:第0天和第7天分别给予LPS 1 ng/kg静脉推注,随后以0.5 ng/kg/hr持续静脉输注3小时。
- CytoSorb组在首次LPS攻击期间接受CytoSorb血液灌流,对照组无干预。
研究设计与关键结果
- 研究类型:人体实验性内毒素血症模型研究,样本量24人,健康男性志愿者,比较首次LPS攻击期间CytoSorb血液灌流与无干预。
- 主要终点:首次LPS攻击期间,与对照组相比,CytoSorb组血浆TNF降低58%(p<0.0001)、IL-6降低71%(p=0.003)、IL-8降低48%(p=0.02)、IL-10降低26%(p=0.03)。
- 第二次LPS攻击期间,两组细胞因子反应无差异。
证据类型、等级与局限
- 证据类型:人体实验性内毒素血症模型研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,CytoSorb疗法可能对以细胞因子过度释放为特征的疾病状态有益。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The CytoSorb hemoadsorption device has been demonstrated to be capable of clearing inflammatory cytokines, but has not yet been shown to attenuate plasma cytokine concentrations. We investigated the effects of CytoSorb hemoperfusion on plasma levels of various cytokines using the repeated human experimental endotoxemia model, a highly standardized and reproducible human in vivo model of systemic inflammation and immunological tolerance induced by administration of bacterial lipopolysaccharide (LPS).
METHODS: Twenty-four healthy male volunteers (age 18-35) were intravenously challenged with LPS (a bolus of 1 ng/kg followed by continuous infusion of 0.5 ng/kg/hr for three hours) twice: on day 0 to quantify the initial cytokine response and on day 7 to quantify the degree of endotoxin tolerance. Subjects either received CytoSorb hemoperfusion during the first LPS challenge (CytoSorb group), or no intervention (control group). Plasma cytokine concentrations and clearance rates were determined serially. This study was registered at ClinicalTrials.gov (NCT04643639, date of registration November 24th 2020).
RESULTS: LPS administration led to a profound increase in plasma cytokine concentrations during both LPS challenge days. Compared to the control group, significantly lower plasma levels of tumor necrosis factor (TNF, - 58%, p < 0.0001), interleukin (IL)-6 ( - 71%, p = 0.003), IL-8 ( - 48%, p = 0.02) and IL-10 ( - 26%, p = 0.03) were observed in the CytoSorb group during the first LPS challenge. No differences in cytokine responses were observed during the second LPS challenge.
CONCLUSIONS: CytoSorb hemoperfusion effectively attenuates circulating cytokine concentrations during systemic inflammation in humans in vivo, whereas it does not affect long-term immune function. Therefore, CytoSorb therapy may be of benefit in conditions characterized by excessive cytokine release.
参考来源
- Jansen A, Waalders NJB, van Lier DPT, et al. CytoSorb hemoperfusion markedly attenuates circulating cytokine concentrations during systemic inflammation in humans in vivo. Crit Care. 2023. PMID: 36945034. doi:10.1186/s13054-023-04391-z
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。